OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
Nicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e62-e74
Closed Access | Times Cited: 43
Nicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e62-e74
Closed Access | Times Cited: 43
Showing 1-25 of 43 citing articles:
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Blood (2024) Vol. 144, Iss. 17, pp. 1813-1820
Closed Access | Times Cited: 9
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Blood (2024) Vol. 144, Iss. 17, pp. 1813-1820
Closed Access | Times Cited: 9
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT
Nicola Polverelli, Edouard F. Bonneville, Liesbeth C. de Wreede, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 993-996
Closed Access | Times Cited: 6
Nicola Polverelli, Edouard F. Bonneville, Liesbeth C. de Wreede, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 993-996
Closed Access | Times Cited: 6
Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 5, pp. e383-e389
Closed Access | Times Cited: 5
Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 5, pp. e383-e389
Closed Access | Times Cited: 5
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Tania Jain, Noel Estrada‐Merly, María Queralt Salas, et al.
Blood Advances (2024) Vol. 8, Iss. 16, pp. 4281-4293
Open Access | Times Cited: 4
Tania Jain, Noel Estrada‐Merly, María Queralt Salas, et al.
Blood Advances (2024) Vol. 8, Iss. 16, pp. 4281-4293
Open Access | Times Cited: 4
Clearance of Driver Mutations after Transplantation for Myelofibrosis
Nico Gagelmann, Marie Quarder, Anita Badbaran, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 2, pp. 150-160
Closed Access
Nico Gagelmann, Marie Quarder, Anita Badbaran, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 2, pp. 150-160
Closed Access
It's More Than Complex: Further Insights Into TP53 in MPN
Nico Gagelmann, Nicolaus Krogër
American Journal of Hematology (2025)
Open Access
Nico Gagelmann, Nicolaus Krogër
American Journal of Hematology (2025)
Open Access
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
Giuseppe Gaetano Loscocco, Paola Guglielmelli
American Journal of Hematology (2025)
Open Access
Giuseppe Gaetano Loscocco, Paola Guglielmelli
American Journal of Hematology (2025)
Open Access
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review
Nico Gagelmann, Nicolaus Kröger
American Journal of Hematology (2025)
Open Access
Nico Gagelmann, Nicolaus Kröger
American Journal of Hematology (2025)
Open Access
Non-myeloablative Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis. A Population-Based Study from Eastern Denmark
Morten Orebo Holmström, Lia Minculescu, K. Nørgaard, et al.
Transplantation and Cellular Therapy (2025)
Open Access
Morten Orebo Holmström, Lia Minculescu, K. Nørgaard, et al.
Transplantation and Cellular Therapy (2025)
Open Access
Editorial: Allogenic hematopoietic cell transplant in hematological malignancies: controversies and perspective
Salvatore Leotta, Sabrina Giammarco, Jacopo Mariotti
Frontiers in Oncology (2025) Vol. 15
Open Access
Salvatore Leotta, Sabrina Giammarco, Jacopo Mariotti
Frontiers in Oncology (2025) Vol. 15
Open Access
Neutrophils in BCR::ABL1 negative MPN: Contributors or bystanders of fibrosis?
Gaël Vermeersch, Mieke Gouwy, Paul Proost, et al.
Blood Reviews (2025), pp. 101285-101285
Closed Access
Gaël Vermeersch, Mieke Gouwy, Paul Proost, et al.
Blood Reviews (2025), pp. 101285-101285
Closed Access
Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes
Sarah Wall, Roni Tamari, Zachariah DeFilipp, et al.
Annals of Hematology (2025)
Open Access
Sarah Wall, Roni Tamari, Zachariah DeFilipp, et al.
Annals of Hematology (2025)
Open Access
Clearance of Driver Mutations in Myelofibrosis
New England Journal of Medicine (2025) Vol. 392, Iss. 13, pp. 1348-1349
Closed Access
New England Journal of Medicine (2025) Vol. 392, Iss. 13, pp. 1348-1349
Closed Access
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 978-981
Closed Access | Times Cited: 2
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 978-981
Closed Access | Times Cited: 2
Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
Adrián Mosquera Orgueira, Eduardo Arellano‐Rodrigo, Marta Garrote, et al.
HemaSphere (2024) Vol. 8, Iss. 3
Open Access | Times Cited: 2
Adrián Mosquera Orgueira, Eduardo Arellano‐Rodrigo, Marta Garrote, et al.
HemaSphere (2024) Vol. 8, Iss. 3
Open Access | Times Cited: 2
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study
Francesca Palandri, Elena Maria Elli, Erika Morsia, et al.
Cancer (2024)
Open Access | Times Cited: 2
Francesca Palandri, Elena Maria Elli, Erika Morsia, et al.
Cancer (2024)
Open Access | Times Cited: 2
Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation
Nico Gagelmann, Claudia Schuh, Robert Zeiser, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 10, pp. 1011.e1-1011.e13
Open Access | Times Cited: 2
Nico Gagelmann, Claudia Schuh, Robert Zeiser, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 10, pp. 1011.e1-1011.e13
Open Access | Times Cited: 2
Clinical and Immune Effects of Peri‐Transplantation JAK Inhibition for Myelofibrosis
Kristin Rathje, Nico Gagelmann, Anita Badbaran, et al.
American Journal of Hematology (2024)
Open Access | Times Cited: 2
Kristin Rathje, Nico Gagelmann, Anita Badbaran, et al.
American Journal of Hematology (2024)
Open Access | Times Cited: 2
Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation
Nico Gagelmann, Claudia Schuh, Sarah Flossdorf, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1540-1549
Open Access | Times Cited: 1
Nico Gagelmann, Claudia Schuh, Sarah Flossdorf, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1540-1549
Open Access | Times Cited: 1
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms
Giuseppe Gaetano Loscocco, Barbara Mora, Naseema Gangat
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Giuseppe Gaetano Loscocco, Barbara Mora, Naseema Gangat
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Hypomethylating agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation
Dat Ngo, Jose Tinajero, Abdullah Ladha, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 11, pp. 1091.e1-1091.e8
Closed Access | Times Cited: 1
Dat Ngo, Jose Tinajero, Abdullah Ladha, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 11, pp. 1091.e1-1091.e8
Closed Access | Times Cited: 1
Advances in Stem Cell Transplantation for Myelofibrosis
Akhil Rajendra, Vikas Gupta
Current Hematologic Malignancy Reports (2024)
Closed Access | Times Cited: 1
Akhil Rajendra, Vikas Gupta
Current Hematologic Malignancy Reports (2024)
Closed Access | Times Cited: 1
Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis
Sigrid Machherndl‐Spandl, Sarah Hannouf, Alexander Nikoloudis, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3257-3257
Open Access | Times Cited: 1
Sigrid Machherndl‐Spandl, Sarah Hannouf, Alexander Nikoloudis, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3257-3257
Open Access | Times Cited: 1
Navigating ‘grey areas’ and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT
Nicola Polverelli, Juan Carlos Hernández‐Boluda, Nico Gagelmann, et al.
Bone Marrow Transplantation (2024)
Closed Access | Times Cited: 1
Nicola Polverelli, Juan Carlos Hernández‐Boluda, Nico Gagelmann, et al.
Bone Marrow Transplantation (2024)
Closed Access | Times Cited: 1
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib
Haifa Kathrin Al‐Ali, Andrew Kuykendall, Catherine Ellis, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4064-4064
Open Access | Times Cited: 1
Haifa Kathrin Al‐Ali, Andrew Kuykendall, Catherine Ellis, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4064-4064
Open Access | Times Cited: 1
